山外山(688410) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥140,442,812.07, a decrease of 22.39% compared to ¥180,952,616.98 in the same period last year[4]. - Net profit attributable to shareholders was ¥16,186,258.95, down 65.84% from ¥47,377,471.95 year-on-year[4]. - The net profit after deducting non-recurring gains and losses was ¥12,889,119.31, reflecting a 71.73% decline compared to ¥45,596,087.16 in the previous year[4]. - The basic and diluted earnings per share were both ¥0.0505, a decrease of 65.74% from ¥0.2197 in the same period last year[5]. - The weighted average return on net assets was 0.98%, down 1.85 percentage points from 2.83% year-on-year[5]. - Total operating revenue for the first three quarters of 2024 was CNY 417,972,866.46, a decrease of 27.4% compared to CNY 575,632,073.38 in the same period of 2023[24]. - Net profit for the first three quarters of 2024 was CNY 59,846,675.96, compared to CNY 180,332,969.64 in the same period of 2023, indicating a decline of 66.8%[26]. - The net profit attributable to shareholders of the parent company for the first three quarters of 2024 is CNY 61,943,138.86, a decrease from CNY 181,617,914.40 in the same period of 2023, representing a decline of approximately 66.1%[28]. - The basic and diluted earnings per share for the first three quarters of 2024 are CNY 0.1935, down from CNY 0.5652 in the same period of 2023, indicating a decrease of about 65.8%[28]. Research and Development - R&D investment totaled ¥14,334,204.26, an increase of 33.35% from ¥10,749,362.96 in the same period last year, representing 10.21% of operating revenue[5]. - R&D investment increased by 59.39% year-on-year in the first nine months of 2024, with 183 R&D personnel, a 42.97% increase[13]. - Research and development expenses increased to CNY 40,961,117.55 in the first three quarters of 2024, up from CNY 25,336,266.89 in 2023, representing a growth of 61.6%[26]. Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date was ¥64,740,527.40, compared to a negative cash flow of ¥102,726,794.05 in the same period last year[4]. - The cash flow from operating activities improved significantly due to enhanced management practices[10]. - The net cash flow from operating activities for the first three quarters of 2024 is CNY 64,740,527.40, compared to a negative cash flow of CNY -102,726,794.05 in the same period of 2023, showing a significant improvement[30]. - The total cash inflow from operating activities for the first three quarters of 2024 is CNY 484,616,117.20, down from CNY 545,137,199.19 in the same period of 2023, reflecting a decrease of approximately 11.1%[30]. - The total cash outflow from operating activities for the first three quarters of 2024 is CNY 419,875,589.80, compared to CNY 647,863,993.24 in the same period of 2023, indicating a reduction of about 35.1%[30]. - The total cash and cash equivalents at the end of the third quarter of 2024 is CNY 857,799,836.14, down from CNY 1,348,383,989.71 at the end of the same period in 2023[31]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,928,520,994.07, a decrease of 0.37% from the previous year-end[5]. - The company's total assets amounted to CNY 1,928,520,994.07, slightly down from CNY 1,935,769,279.42 at the end of the previous year[24]. - Total liabilities increased to CNY 240,635,843.92 from CNY 240,257,646.40, showing a rise of 0.16%[24]. - The company's equity attributable to shareholders was CNY 1,691,859,725.14, a slight decrease from CNY 1,697,389,745.10 in the previous year[24]. - The company reported accounts receivable of RMB 103,290,788.59 as of September 30, 2024, compared to RMB 102,332,412.80 at the end of 2023, reflecting a slight increase of about 0.9%[22]. - The company’s fixed assets decreased from RMB 113,403,600.76 at the end of 2023 to RMB 109,372,067.86, indicating a decrease of approximately 3.0%[22]. - The company reported a significant increase in accounts payable, which rose to CNY 38,136,257.36 from CNY 24,806,248.99, reflecting a growth of 53.5%[24]. Market Position and Strategy - The company ranked first in market procurement for both hemodialysis machines and continuous renal replacement therapy (CRRT) devices in the third quarter of 2024[10]. - The company is actively engaging in market expansion and new product development strategies as part of its growth initiatives[18]. - The number of blood purification equipment tenders nationwide decreased by 23.45% year-on-year, with 9,724 units in the first nine months of 2024[10]. Shareholder Actions - The company completed a capital reserve distribution on July 9, 2024, increasing shares by 0.49 per share, totaling 105,667,561 shares[7]. - The company has repurchased a total of 2,817,364 shares, which is 0.88% of the total share capital of 321,315,646 shares, with a total expenditure of RMB 49,994,660.63[19]. - The maximum repurchase price was adjusted to RMB 25.37 per share following the 2023 annual equity distribution[19]. - The company approved a stock incentive plan for 2023, granting reserved restricted stock to eligible participants[18]. - The company implemented an employee stock ownership plan in the second quarter of 2024, increasing share-based payment expenses by 16.6961 million yuan[10].